MYD88-Mutated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma as a Distinctive Molecular Subgroup Is Associated with Atypical Immunophenotypes in Chinese Patients

Chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is a heterogeneous disease in Western and Chinese populations, and it is still not well characterized in Chinese patients. Based on a large cohort of newly diagnosed CLL/SLL patients from China, we investigated immunophenotypes, genetic abnormalities, and their correlations. Eighty-four percent of the CLL/SLL patients showed typical immunophenotypes with scores of 4 or 5 points in the Royal Marsden Hospital (RMH) scoring system (classic group), and the remaining 16% of patients were atypical with scores lower than 4 points (atypical group). Trisomy 12 and variants of TP53, NOTCH1, SF3B1, ATM, and MYD88 were the most recurrent genetic aberrations. Additionally, unsupervised genomic analysis based on molecular genetics revealed distinctive characteristics of MYD88 variants in CLL/SLL. By overlapping different correlation grouping analysis from genetics to immunophenotypes, the results showed MYD88 variants to be highly related to atypical CLL/SLL immunophenotypes. Furthermore, compared with mantle cell lymphoma (MCL), the genetic landscape showed potential value in clinical differential diagnosis of atypical CLL/SLL and MCL patients. These results reveal immunophenotypic and genetic features, and may provide insights into the tumorigenesis and clinical management of Chinese CLL/SLL patients.

[1]  Xin Wang,et al.  Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia , 2022, Frontiers in Oncology.

[2]  Donghua Zhang,et al.  A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia , 2021, Cancer medicine.

[3]  R. Gale,et al.  High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia , 2021, Leukemia.

[4]  E. Montserrat,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Gale,et al.  Ethnic and geographic diversity of chronic lymphocytic leukaemia , 2020, Leukemia.

[6]  Xu Wang,et al.  MYD88 L265P Elicits Mutation-specific Ubiquitination to Drive NF-κB Activation and Lymphomagenesis. , 2020, Blood.

[7]  M. Routbort,et al.  Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features , 2020, Blood Cancer Journal.

[8]  W. Xu,et al.  98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia , 2019, Cancer medicine.

[9]  F. Bosch,et al.  Chronic lymphocytic leukaemia: from genetics to treatment , 2019, Nature Reviews Clinical Oncology.

[10]  L. Shih,et al.  Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia , 2019, British journal of haematology.

[11]  S. Ryder.  #CRISPRbabies: Notes on a Scandal , 2018, The CRISPR journal.

[12]  R. Gale,et al.  Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China? , 2018, Leukemia research.

[13]  K. Young,et al.  MYD88 L265P Mutation in Lymphoid Malignancies. , 2018, Cancer research.

[14]  T. Shanafelt,et al.  Chronic lymphocytic leukaemia , 2018, The Lancet.

[15]  Felicia A Tucci,et al.  Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals. , 2018, Blood.

[16]  M. Wood.  Notes on a scandal , 2017, Nature.

[17]  Jian-yong Li,et al.  MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene , 2017, Blood Cancer Journal.

[18]  A. Bagg,et al.  Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets , 2016, Leukemia & lymphoma.

[19]  K. Stamatopoulos,et al.  Prognostic relevance of MYD88 mutations in CLL: the jury is still out. , 2015, Blood.

[20]  R. Gale,et al.  The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? , 2015, Blood reviews.

[21]  E. Campo,et al.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.

[22]  Hee-Jin Kim,et al.  Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior , 2013, International Journal of Hematology.

[23]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[24]  L. Cro,et al.  The clinical and biological features of a series of immunophenotypic variant of B‐CLL , 2010, European journal of haematology.

[25]  C. Pascutto,et al.  IGHV unmutated status influences outcome more than IGHV1-69 gene usage per se in patients with chronic lymphocytic leukemia. , 2009, Clinical lymphoma & myeloma.

[26]  H. Nakahashi,et al.  Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders , 2009, Cancer science.

[27]  N. McMillan,et al.  Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia , 2008, Cancer biology & therapy.

[28]  W. Xu,et al.  Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. , 2008, Leukemia research.

[29]  J. Gribben,et al.  Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia , 2005, British journal of haematology.

[30]  D. Catovsky,et al.  Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). , 1997, American journal of clinical pathology.

[31]  D. Catovsky,et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.

[32]  M. Jarošová,et al.  Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center. , 2015, Neoplasma.